Rapalogix Health
Pioneering a new category of longevity-based skin health
New York, United States · Founded 2024 · $20.0M raised
- Headquarters
- New York
- Employees
- 1–10
- Founded
- 2024
- Business Model
- B2B
- Website
- rapalogix.com
- Total Funding
- $20.0M
- Last Round
- $20.0M Series AJun 2026
- Rounds
- 1
About
Rapalogix Health is a biotechnology company focused on translating longevity science into transformative dermatological therapeutics and skincare solutions. The company's scientific platform is built around TORC1 (a component of mTOR), one of the most extensively studied cellular pathways associated with aging. By selectively inhibiting TORC1, Rapalogix aims to address the underlying biology of skin aging and treat dermatological disorders including rosacea, acne, atopic dermatitis, and psoriasis. The company develops both prescription therapeutics—advancing RLX-202, a selective TORC1 inhibitor targeting chronic skin conditions with an IND planned for 2028—and the Re-Q Health professional skincare line powered by RLX-201, available exclusively through dermatology and aesthetic physician practices. Founded by skin longevity scientist Rahul Mehta PhD, dermatologist Doris Day MD, and healthcare executive Brent Saunders.
Summary
Rapalogix Health is a Biotech company based in New York, United States, founded in 2024. It has raised $20.0M in total across 1 round, most recently a $20.0M Series A round in Jun 2026. Investors include Quiet Capital.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jun 2026
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...